Sangamo Therapeutics (SGMO) Stock Price, Quote & News

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 970 6000

Website: www.sangamo.com

Address:

501 Canal Blvd, Richmond, United States

tcamp12 Jun. 17 at 11:02 AM

$SGMO Lilly buys Verve Therapeutics

0 · Reply

biotech Jun. 17 at 10:52 AM

$LLY buys $VERV for #PCSK9 "Verve's lead program (VERVE-102) is a potential first-in-class in vivo gene editing medicine targeting PCSK9, a gene linked to cholesterol levels and cardiovascular health" re $SGMO 99% PCSK9 #epigenetic eding

1 · Reply

biotech Jun. 17 at 8:53 AM

$LLY $VERV $XBI ... HCW Neuro Perspectives Hybrid Conference $SGMO Sangamo talking about their $LLY Eli Lilly partnership STAC-BBB says delivery is everyting in genomic medicine in talks for further capsid deals #MINT: world moved away from nuclease https://journey.ct.events/view/1055105d-0956-4bb2-9e54-eae6c85c8490

2 · Reply

EddieH2020 Jun. 16 at 8:21 PM

$SGMO More free shares for these idiots lmao

0 · Reply

SilentSniper Jun. 16 at 8:11 PM

$SGMO We could even get a halt with news pending and then release of either Fabry partnership/data news..

1 · Reply

SilentSniper Jun. 16 at 8:00 PM

$SGMO getting close to Fabry data/partnership news..Good Luck gang!

0 · Reply

biotech Jun. 16 at 7:11 PM

$SGMO CC 7:00 AM EDT tomorrow

2 · Reply

JimiJoJeeter Jun. 16 at 6:11 PM

$SGMO anyone care to speculate on the Fabry data press release will come before the end of the month? 1. This week. 2. Next week. 3. Last day of the month. 4 They will fail to meet their own end of the month promise.

1 · Reply

NancyPelosi____insider Jun. 16 at 5:28 PM

$CRDL $CRSP $SGMO $EVFM

0 · Reply

michelo99999 Jun. 16 at 2:40 PM

$SGMO where is the 8K form with the results of the vote? why the delay?

2 · Reply

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

May 12, 2025, 6:26 PM EDT - 5 weeks ago

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12, 2025, 6:23 PM EDT - 5 weeks ago

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12, 2025, 4:00 PM EDT - 5 weeks ago

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 6, 2025, 4:35 PM EDT - 5 weeks ago

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025, 8:30 AM EDT - 5 weeks ago

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Apr 28, 2025, 4:31 PM EDT - 7 weeks ago

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Apr 4, 2025, 2:57 PM EDT - 2 months ago

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Apr 3, 2025, 4:01 PM EDT - 2 months ago

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Mar 17, 2025, 6:29 PM EDT - 3 months ago

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:01 PM EDT - 3 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 4:05 PM EST - 3 months ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Feb 6, 2025, 8:05 AM EST - 4 months ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Jan 15, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Jan 14, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Jan 13, 2025, 10:00 AM EST - 5 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 12, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

Jan 10, 2025, 10:00 AM EST - 5 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 9, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

Jan 8, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

Jan 7, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

Jan 6, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

Jan 5, 2025, 10:00 AM EST - 5 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 3, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

Jan 2, 2025, 6:00 PM EST - 5 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Jan 2, 2025, 4:00 PM EST - 5 months ago

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Jan 2, 2025, 3:05 PM EST - 5 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Jan 2, 2025, 10:15 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation

Dec 31, 2024, 12:01 PM EST - 5 months ago

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

Dec 31, 2024, 11:22 AM EST - 5 months ago

Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact

PFE

Dec 31, 2024, 11:20 AM EST - 5 months ago

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

Dec 31, 2024, 9:14 AM EST - 5 months ago

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

PFE

Dec 31, 2024, 8:47 AM EST - 5 months ago

Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Dec 30, 2024, 4:34 PM EST - 6 months ago

Sangamo to reclaim hemophilia A therapy rights post Pfizer termination

PFE

Dec 30, 2024, 4:15 PM EST - 6 months ago

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development of Giroctocogene Fitelparvovec

tcamp12 Jun. 17 at 11:02 AM

$SGMO Lilly buys Verve Therapeutics

0 · Reply

biotech Jun. 17 at 10:52 AM

1 · Reply

biotech Jun. 17 at 8:53 AM

2 · Reply

EddieH2020 Jun. 16 at 8:21 PM

$SGMO More free shares for these idiots lmao

0 · Reply

SilentSniper Jun. 16 at 8:11 PM

$SGMO We could even get a halt with news pending and then release of either Fabry partnership/data news..

1 · Reply

SilentSniper Jun. 16 at 8:00 PM

$SGMO getting close to Fabry data/partnership news..Good Luck gang!

0 · Reply

biotech Jun. 16 at 7:11 PM

$SGMO CC 7:00 AM EDT tomorrow

2 · Reply

JimiJoJeeter Jun. 16 at 6:11 PM

1 · Reply

NancyPelosi____insider Jun. 16 at 5:28 PM

$CRDL $CRSP $SGMO $EVFM

0 · Reply

michelo99999 Jun. 16 at 2:40 PM

$SGMO where is the 8K form with the results of the vote? why the delay?

2 · Reply

biotech Jun. 16 at 2:30 PM

$SGMO Did not know #ROCHE is still into #Hemophilia A #Gene #Therapy with introducing an enhanced function factor VIII variant (SPK-8011 #QQ) This “next generation” gene therapy is planned to be studied in a Phase 2b clinical trial sponsored by Roche and Genetech... re Roche partner $SGMO #GirFit for sale ...

0 · Reply

Xfaster Jun. 16 at 1:43 PM

$SGMO

0 · Reply

jac05010 Jun. 16 at 1:39 PM

$SGMO ends up today sub .45, no reason to invest here. Would spike over $1 if they fired Sandy

0 · Reply

brucelee12 Jun. 16 at 1:38 PM

$SGMO red 3days.. fuck!!

0 · Reply

biotech Jun. 16 at 1:33 PM

$SGMO hhhmmmmm washington june 20 2025 ?

2 · Reply

Estimize Jun. 16 at 1:03 PM

Wall St is expecting -0.02 EPS for $SGMO Q2 [Reporting 08/12 AMC] http://www.estimize.com/intro/sgmo?chart=historical&metric_name=eps&utm_c

1 · Reply

tcamp12 Jun. 16 at 10:42 AM

$SGMO Sarepta Therapeutics 2nd patient dies.

4 · Reply

Newbilly Jun. 16 at 2:38 AM

$SGMO This is our week.. Feeling it !!

2 · Reply

TheFrenchBuzz Jun. 15 at 8:31 PM

$SGMO June 30, 23:59.999

2 · Reply

mike_swiss_r Jun. 15 at 1:50 PM

$SGMO So when is the Fabry formal data release??

1 · Reply

Flipperthedolphin Jun. 13 at 9:01 PM

$SGMO big after hours moves (11k shares!!!!)

2 · Reply

Crash_Bash Jun. 13 at 8:56 PM

$SGMO lets get next week perfectly excuted Sandy... 1) Monday: annouce Fabry data 2) Tuesday: fireside chate to discuss fabry and neuro 3) Wednesday: Fabry deal 4) Thursday and Friday: Party Lets goooooo

5 · Reply

Market Cap	114.49M
Revenue (ttm)	57.80M
Net Income (ttm)	-97.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-169.45%
Debt to Equity Ratio	0.00

Volume	2,601,300
Avg Vol	6,415,910
Day's Range	N/A - N/A
Shares Out	233.17M
Stochastic %K	29%
Beta	1.19
Analysts	Strong Sell
Price Target	$4.10